Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials
Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint.
The company said the trials showed its drug compound fasinumab, an investigational Nerve Growth Factor (NGF) antibody, showed statistically significant improvement in pain relief as well as improvements in the secondary measure evaluating physical function.
George Yancopoulos, chief scientific officer of Regeneron, says: “Chronic osteoarthritis is a common cause of pain, disability, and productivity loss for older adults. There is a real need for new, non-opioid pain therapies that can provide relief to patients without the toxicity and potential for abuse of currently available opioid treatments. We had previously evaluated an intravenous formulation of fasinumab in osteoarthritis patients, and this is our first trial of a convenient subcutaneous monthly regimen.”
Because of prior concerns with other anti-NGF therapies regarding the possible risk of joint damage, the study incorporated extensive imaging and analyses at baseline and during the study, of index and non-index joints, with particular focus on subchondral insufficiency fractures (SIF), osteonecrosis (ON) and rapidly progressive osteoarthritis (RPOA), Regeneron said in a statement.
German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has …
Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia …